Recent Updates
  • My dumb and fat ahh fell for it
    My dumb and fat ahh fell for it
    Like
    Love
    Wow
    3
    · 0 Comments ·0 Shares ·86K Views ·0 Reviews
  • Gifted by god?
    Gifted by god?
    Like
    Love
    Wow
    3
    · 0 Comments ·0 Shares ·86K Views ·0 Reviews
  • Features no one asked for
    Features no one asked for
    Like
    Love
    Wow
    3
    · 0 Comments ·0 Shares ·82K Views ·0 Reviews
  • Hell nah!
    Hell nah!
    Like
    Love
    Wow
    3
    · 0 Comments ·0 Shares ·86K Views ·0 Reviews
  • We had some surprisingly friendly guests visiting our camp site
    We had some surprisingly friendly guests visiting our camp site
    Like
    Love
    Wow
    3
    · 0 Comments ·0 Shares ·14K Views ·0 Reviews
  • Global Afamelanotide Market (2024–2032): USD 136.27M to USD 258.01M Growth at 9.1% CAGR
    Global Afamelanotide Market is projected to grow from USD 136.27 million in 2024 to USD 258.01 million by 2032, registering a strong CAGR of 9.1%. Afamelanotide (SCENESSE®), the first approved treatment for EPP, enhances melanin production to improve sunlight tolerance in patients with severe phototoxic disorders. Rising awareness of rare diseases, expanding clinical trials in vitiligo and photodermatoses, and broader regulatory support are fueling market demand globally.
    Global Afamelanotide Market (2024–2032): USD 136.27M to USD 258.01M Growth at 9.1% CAGR Global Afamelanotide Market is projected to grow from USD 136.27 million in 2024 to USD 258.01 million by 2032, registering a strong CAGR of 9.1%. Afamelanotide (SCENESSE®), the first approved treatment for EPP, enhances melanin production to improve sunlight tolerance in patients with severe phototoxic disorders. Rising awareness of rare diseases, expanding clinical trials in vitiligo and photodermatoses, and broader regulatory support are fueling market demand globally.
    0 Comments ·0 Shares ·75 Views ·0 Reviews
More Stories